Irska - engleski - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/250mcg microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Irska - engleski - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - salmeterol; fluticasone propionate - inhalation powder, pre-dispensed - 50/250 microgram(s) - salmeterol and fluticasone

Irska - engleski - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25mcg/250 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Australija - engleski - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 400 microgram - nasal drops - excipient ingredients: polysorbate 20; sorbitan monolaurate; monobasic sodium phosphate; dibasic sodium phosphate; sodium chloride; water for injections - indications: for the treatment of mild to moderate nasal polyps and associated symptoms of nasal obstruction in adults and adolescents over 16 years of age.

Irska - engleski - HPRA (Health Products Regulatory Authority)

neutec inhaler ireland limited - salmeterol; fluticasone propionate - inhalation powder, pre-dispensed - 50 microgram / 250 microgram(s)/dose - salmeterol and fluticasone

Irska - engleski - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/250 microgram(s) - salmeterol and fluticasone

Australija - engleski - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. seroflo ciphaler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Irska - engleski - HPRA (Health Products Regulatory Authority)

lexon pharmaceuticals (ireland) limited - salmeterol; fluticasone propionate - inhalation powder, pre-dispensed - 50/250 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Irska - engleski - HPRA (Health Products Regulatory Authority)

b & s healthcare - fluticasone propionate - pressurised inhalation suspension - 250 microgram - glucocorticoids

Irska - engleski - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - fluticasone propionate; salmeterol xinafoate - pressurised inhalation, suspension - 25/250 mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone